NDC 0245-0812

TOSYMRA

Sumatriptan

TOSYMRA is a Nasal Spray in the Human Prescription Drug category. It is labeled and distributed by Upsher-smith Laboratories, Llc. The primary component is Sumatriptan.

Product ID0245-0812_a39c33cb-bf6c-4730-8159-49c7c02b224a
NDC0245-0812
Product TypeHuman Prescription Drug
Proprietary NameTOSYMRA
Generic NameSumatriptan
Dosage FormSpray
Route of AdministrationNASAL
Marketing Start Date2019-07-08
Marketing CategoryNDA /
Application NumberNDA210884
Labeler NameUpsher-Smith Laboratories, LLC
Substance NameSUMATRIPTAN
Active Ingredient Strength10 mg/.1mL
Pharm ClassesSerotonin 1b Receptor Agonists [MoA], Serotonin 1d Receptor Agonists [MoA], Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]
NDC Exclude FlagN
Listing Certified Through2023-12-31

Packaging

NDC 0245-0812-61

6 BLISTER PACK in 1 CARTON (0245-0812-61) > 1 BOTTLE, SPRAY in 1 BLISTER PACK (0245-0812-89) > .1 mL in 1 BOTTLE, SPRAY (0245-0812-59)
Marketing Start Date2021-09-01
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "TOSYMRA" or generic name "Sumatriptan"

NDCBrand NameGeneric Name
0245-0812TOSYMRAsumatriptan
67857-812TOSYMRATOSYMRA
0173-0449IMITREXsumatriptan
0173-0478IMITREXsumatriptan
0173-0479IMITREXsumatriptan
0173-0523IMITREXsumatriptan
0173-0524IMITREXsumatriptan
0173-0735IMITREXsumatriptan
0173-0736IMITREXsumatriptan
0173-0737IMITREXsumatriptan
0173-0739IMITREXsumatriptan
0143-9638SUMATRIPTANsumatriptan
0527-1818SumatriptanSumatriptan
0527-1859SumatriptanSumatriptan
0781-6523SUMATRIPTANsumatriptan
0781-6524SUMATRIPTANsumatriptan

Trademark Results [TOSYMRA]

Mark Image

Registration | Serial
Company
Trademark
Application Date
TOSYMRA
TOSYMRA
88775112 not registered Live/Pending
UPSHER-SMITH LABORATORIES, LLC
2020-01-27
TOSYMRA
TOSYMRA
88390100 not registered Live/Pending
UPSHER-SMITH LABORATORIES, LLC
2019-04-17
TOSYMRA
TOSYMRA
87815803 not registered Live/Pending
Promius Pharma, LLC
2018-03-01

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.